We appreciate the letter from Marjan Attaei and Salim Yusuf in which they express concern that the cost estimates for treating hypertension cited by the Lancet Commission on Hypertension1 might be misleading because it is unclear whether the figures cited by the Commission represent cost per capita or cost per patient treated, and because subsequent data collected by Attaei and Yusuf indicate that cost per patient treated might be higher than that quoted by the Commission.
